Basal  ||| S:0 E:6 ||| FW
elevated  ||| S:6 E:15 ||| FW
serum  ||| S:15 E:21 ||| FW
calcium  ||| S:21 E:29 ||| FW
phosphate  ||| S:29 E:39 ||| FW
product  ||| S:39 E:47 ||| NN
as  ||| S:47 E:50 ||| IN
an  ||| S:50 E:53 ||| DT
independent  ||| S:53 E:65 ||| JJ
risk  ||| S:65 E:70 ||| NN
factor  ||| S:70 E:77 ||| NN
for  ||| S:77 E:81 ||| IN
mortality  ||| S:81 E:91 ||| NN
in  ||| S:91 E:94 ||| IN
patients  ||| S:94 E:103 ||| NNS
with  ||| S:103 E:108 ||| IN
fractures  ||| S:108 E:118 ||| NN
of  ||| S:118 E:121 ||| IN
the  ||| S:121 E:125 ||| DT
proximal  ||| S:125 E:134 ||| JJ
femur-A  ||| S:134 E:142 ||| JJ
20  ||| S:142 E:145 ||| CD
year  ||| S:145 E:150 ||| NN
observation  ||| S:150 E:162 ||| NN
study  ||| S:162 E:168 ||| NN
Fractures  ||| S:168 E:178 ||| NNS
of  ||| S:178 E:181 ||| IN
the  ||| S:181 E:185 ||| DT
proximal  ||| S:185 E:194 ||| JJ
femur  ||| S:194 E:200 ||| NNS
are  ||| S:200 E:204 ||| VBP
a  ||| S:204 E:206 ||| DT
significant  ||| S:206 E:218 ||| JJ
cause  ||| S:218 E:224 ||| NN
of  ||| S:224 E:227 ||| IN
mortality  ||| S:227 E:237 ||| NN
and  ||| S:237 E:241 ||| CC
morbidity  ||| S:241 E:251 ||| NN
in  ||| S:251 E:254 ||| IN
the  ||| S:254 E:258 ||| DT
elderly  ||| S:258 E:266 ||| JJ
population ||| S:266 E:276 ||| NN
.  ||| S:276 E:278 ||| .
Yet  ||| S:278 E:282 ||| RB
predictive  ||| S:282 E:293 ||| JJ
marker  ||| S:293 E:300 ||| NN
of  ||| S:300 E:303 ||| IN
unfavourable  ||| S:303 E:316 ||| JJ
prognosis  ||| S:316 E:326 ||| NNS
are  ||| S:326 E:330 ||| VBP
still  ||| S:330 E:336 ||| RB
lacking ||| S:336 E:343 ||| VBG
.  ||| S:343 E:345 ||| .
Calcium  ||| S:345 E:353 ||| JJ
phosphate  ||| S:353 E:363 ||| JJ
product  ||| S:363 E:371 ||| NN
is  ||| S:371 E:374 ||| VBZ
a  ||| S:374 E:376 ||| DT
marker  ||| S:376 E:383 ||| NN
of  ||| S:383 E:386 ||| IN
osteo-renal  ||| S:386 E:398 ||| JJ
dysregulation ||| S:398 E:411 ||| NN
.  ||| S:411 E:413 ||| .
This  ||| S:413 E:418 ||| DT
study  ||| S:418 E:424 ||| NN
investigated  ||| S:424 E:437 ||| VBD
the  ||| S:437 E:441 ||| DT
role  ||| S:441 E:446 ||| NN
of  ||| S:446 E:449 ||| IN
serum  ||| S:449 E:455 ||| JJ
calcium  ||| S:455 E:463 ||| NN
phosphate  ||| S:463 E:473 ||| NN
product  ||| S:473 E:481 ||| NN
( ||| S:481 E:482 ||| -LRB-
SCPP ||| S:482 E:486 ||| NNP
)  ||| S:486 E:488 ||| -RRB-
levels  ||| S:488 E:495 ||| NNS
as  ||| S:495 E:498 ||| IN
a  ||| S:498 E:500 ||| DT
prognostic  ||| S:500 E:511 ||| JJ
parameter  ||| S:511 E:521 ||| NN
for  ||| S:521 E:525 ||| IN
outcome  ||| S:525 E:533 ||| NN
in  ||| S:533 E:536 ||| IN
those  ||| S:536 E:542 ||| DT
patients ||| S:542 E:550 ||| NNS
.  ||| S:550 E:552 ||| .
A  ||| S:552 E:554 ||| DT
total  ||| S:554 E:560 ||| NN
of  ||| S:560 E:563 ||| IN
3577  ||| S:563 E:568 ||| CD
consecutive  ||| S:568 E:580 ||| JJ
patients  ||| S:580 E:589 ||| NNS
with  ||| S:589 E:594 ||| IN
diagnosed  ||| S:594 E:604 ||| JJ
fractures  ||| S:604 E:614 ||| NN
of  ||| S:614 E:617 ||| IN
the  ||| S:617 E:621 ||| DT
proximal  ||| S:621 E:630 ||| JJ
femur  ||| S:630 E:636 ||| NN
were  ||| S:636 E:641 ||| VBD
included  ||| S:641 E:650 ||| VBN
in  ||| S:650 E:653 ||| IN
our  ||| S:653 E:657 ||| PRP$
study  ||| S:657 E:663 ||| NN
( ||| S:663 E:664 ||| -LRB-
72.5 ||| S:664 E:668 ||| NNP
%  ||| S:668 E:670 ||| NN
females ||| S:670 E:677 ||| NNS
) ||| S:677 E:678 ||| -RRB-
.  ||| S:678 E:680 ||| .
SCPP  ||| S:680 E:685 ||| NNP
was  ||| S:685 E:689 ||| VBD
divided  ||| S:689 E:697 ||| VBN
into  ||| S:697 E:702 ||| IN
tertiles ||| S:702 E:710 ||| NNS
:  ||| S:710 E:712 ||| :
< ||| S:712 E:713 ||| SYM
1.92mmol ||| S:713 E:721 ||| CD
( ||| S:721 E:722 ||| -LRB-
2 ||| S:722 E:723 ||| LS
) ||| S:723 E:724 ||| -RRB-
/ ||| S:724 E:725 ||| FW
l ||| S:725 E:726 ||| FW
( ||| S:726 E:727 ||| -LRB-
2 ||| S:727 E:728 ||| LS
) ||| S:728 E:729 ||| -RRB-
,  ||| S:729 E:731 ||| ,
1.93-2.38mmol ||| S:731 E:744 ||| NNP
( ||| S:744 E:745 ||| -LRB-
2 ||| S:745 E:746 ||| LS
) ||| S:746 E:747 ||| -RRB-
/ ||| S:747 E:748 ||| FW
l ||| S:748 E:749 ||| FW
( ||| S:749 E:750 ||| -LRB-
2 ||| S:750 E:751 ||| LS
)  ||| S:751 E:753 ||| -RRB-
and  ||| S:753 E:757 ||| CC
> ||| S:757 E:758 ||| NNP
2.39mmol ||| S:758 E:766 ||| NNP
( ||| S:766 E:767 ||| -LRB-
2 ||| S:767 E:768 ||| LS
) ||| S:768 E:769 ||| -RRB-
/ ||| S:769 E:770 ||| FW
l ||| S:770 E:771 ||| FW
( ||| S:771 E:772 ||| -LRB-
2 ||| S:772 E:773 ||| LS
) ||| S:773 E:774 ||| -RRB-
.  ||| S:774 E:776 ||| .
Data  ||| S:776 E:781 ||| NNP
collection  ||| S:781 E:792 ||| NN
was  ||| S:792 E:796 ||| VBD
performed  ||| S:796 E:806 ||| VBN
prospectively  ||| S:806 E:820 ||| RB
and  ||| S:820 E:824 ||| CC
statistical  ||| S:824 E:836 ||| JJ
evaluation  ||| S:836 E:847 ||| NN
was  ||| S:847 E:851 ||| VBD
performed  ||| S:851 E:861 ||| VBN
retrospectively ||| S:861 E:876 ||| NN
.  ||| S:876 E:878 ||| .
Mean  ||| S:878 E:883 ||| VB
follow  ||| S:883 E:890 ||| VB
up  ||| S:890 E:893 ||| RP
in  ||| S:893 E:896 ||| IN
our  ||| S:896 E:900 ||| PRP$
study  ||| S:900 E:906 ||| NN
group  ||| S:906 E:912 ||| NN
was  ||| S:912 E:916 ||| VBD
11.0±0.3  ||| S:916 E:925 ||| CD
months ||| S:925 E:931 ||| NNS
.  ||| S:931 E:933 ||| .
The  ||| S:933 E:937 ||| DT
mean  ||| S:937 E:942 ||| JJ
age  ||| S:942 E:946 ||| NN
of  ||| S:946 E:949 ||| IN
our  ||| S:949 E:953 ||| PRP$
study  ||| S:953 E:959 ||| NN
group  ||| S:959 E:965 ||| NN
was  ||| S:965 E:969 ||| VBD
79.0  ||| S:969 E:974 ||| CD
years  ||| S:974 E:980 ||| NNS
( ||| S:980 E:981 ||| -LRB-
SEM  ||| S:981 E:985 ||| NNP
±14  ||| S:985 E:989 ||| NNP
years ||| S:989 E:994 ||| NNS
) ||| S:994 E:995 ||| -RRB-
.  ||| S:995 E:997 ||| .
To  ||| S:997 E:1000 ||| TO
facilitate  ||| S:1000 E:1011 ||| VB
analysis ||| S:1011 E:1019 ||| NN
,  ||| S:1019 E:1021 ||| ,
patients  ||| S:1021 E:1030 ||| NNS
were  ||| S:1030 E:1035 ||| VBD
divided  ||| S:1035 E:1043 ||| VBN
in  ||| S:1043 E:1046 ||| IN
two  ||| S:1046 E:1050 ||| CD
groups ||| S:1050 E:1056 ||| NNS
:  ||| S:1056 E:1058 ||| :
≤84  ||| S:1058 E:1062 ||| CD
years  ||| S:1062 E:1068 ||| NNS
( ||| S:1068 E:1069 ||| -LRB-
64.4 ||| S:1069 E:1073 ||| NNP
% ||| S:1073 E:1074 ||| NN
)  ||| S:1074 E:1076 ||| -RRB-
and  ||| S:1076 E:1080 ||| CC
≥85  ||| S:1080 E:1084 ||| CD
years  ||| S:1084 E:1090 ||| NNS
( ||| S:1090 E:1091 ||| -LRB-
35.6 ||| S:1091 E:1095 ||| CD
% ||| S:1095 E:1096 ||| NN
) ||| S:1096 E:1097 ||| -RRB-
,  ||| S:1097 E:1099 ||| ,
and  ||| S:1099 E:1103 ||| CC
mortality  ||| S:1103 E:1113 ||| NN
< ||| S:1113 E:1114 ||| SYM
12  ||| S:1114 E:1117 ||| CD
months  ||| S:1117 E:1124 ||| NNS
was  ||| S:1124 E:1128 ||| VBD
12.4 ||| S:1128 E:1132 ||| CD
%  ||| S:1132 E:1134 ||| NN
( ||| S:1134 E:1135 ||| -LRB-
n=445 ||| S:1135 E:1140 ||| NNP
) ||| S:1140 E:1141 ||| -RRB-
.  ||| S:1141 E:1143 ||| .
In  ||| S:1143 E:1146 ||| IN
our  ||| S:1146 E:1150 ||| PRP$
study  ||| S:1150 E:1156 ||| NN
population  ||| S:1156 E:1167 ||| NN
higher  ||| S:1167 E:1174 ||| RBR
SCPP  ||| S:1174 E:1179 ||| JJ
levels  ||| S:1179 E:1186 ||| NNS
ad  ||| S:1186 E:1189 ||| NN
admission  ||| S:1189 E:1199 ||| NN
were  ||| S:1199 E:1204 ||| VBD
associated  ||| S:1204 E:1215 ||| VBN
with  ||| S:1215 E:1220 ||| IN
a  ||| S:1220 E:1222 ||| DT
markedly  ||| S:1222 E:1231 ||| JJ
elevated  ||| S:1231 E:1240 ||| JJ
mortality ||| S:1240 E:1249 ||| NN
.  ||| S:1249 E:1251 ||| .
In  ||| S:1251 E:1254 ||| IN
a  ||| S:1254 E:1256 ||| DT
multivariate  ||| S:1256 E:1269 ||| JJ
logistic  ||| S:1269 E:1278 ||| JJ
regression  ||| S:1278 E:1289 ||| JJ
model  ||| S:1289 E:1295 ||| NN
adjusted  ||| S:1295 E:1304 ||| VBN
for  ||| S:1304 E:1308 ||| IN
age  ||| S:1308 E:1312 ||| NN
and  ||| S:1312 E:1316 ||| CC
sex ||| S:1316 E:1319 ||| NN
,  ||| S:1319 E:1321 ||| ,
plasma  ||| S:1321 E:1328 ||| JJ
creatinine  ||| S:1328 E:1339 ||| NN
and  ||| S:1339 E:1343 ||| CC
haemoglobin  ||| S:1343 E:1355 ||| NN
at  ||| S:1355 E:1358 ||| IN
admission  ||| S:1358 E:1368 ||| NN
caused  ||| S:1368 E:1375 ||| VBD
a  ||| S:1375 E:1377 ||| DT
1.3  ||| S:1377 E:1381 ||| CD
( ||| S:1381 E:1382 ||| -LRB-
CI ||| S:1382 E:1384 ||| NNP
:  ||| S:1384 E:1386 ||| :
1.01-1.6 ||| S:1386 E:1394 ||| CD
)  ||| S:1394 E:1396 ||| -RRB-
for  ||| S:1396 E:1400 ||| IN
SCPP  ||| S:1400 E:1405 ||| NNP
1.93-2.38mmol ||| S:1405 E:1418 ||| NNP
( ||| S:1418 E:1419 ||| -LRB-
2 ||| S:1419 E:1420 ||| LS
) ||| S:1420 E:1421 ||| -RRB-
/ ||| S:1421 E:1422 ||| FW
l ||| S:1422 E:1423 ||| FW
( ||| S:1423 E:1424 ||| -LRB-
2 ||| S:1424 E:1425 ||| LS
) ||| S:1425 E:1426 ||| -RRB-
,  ||| S:1426 E:1428 ||| ,
and  ||| S:1428 E:1432 ||| CC
a  ||| S:1432 E:1434 ||| DT
1.6  ||| S:1434 E:1438 ||| CD
( ||| S:1438 E:1439 ||| -LRB-
CI ||| S:1439 E:1441 ||| NNP
:  ||| S:1441 E:1443 ||| :
1.2-2.0 ||| S:1443 E:1450 ||| CD
)  ||| S:1450 E:1452 ||| -RRB-
for  ||| S:1452 E:1456 ||| IN
SPP  ||| S:1456 E:1460 ||| NNP
> ||| S:1460 E:1461 ||| NNP
2.39mmol ||| S:1461 E:1469 ||| NNP
( ||| S:1469 E:1470 ||| -LRB-
2 ||| S:1470 E:1471 ||| LS
) ||| S:1471 E:1472 ||| -RRB-
/ ||| S:1472 E:1473 ||| FW
l ||| S:1473 E:1474 ||| FW
( ||| S:1474 E:1475 ||| -LRB-
2 ||| S:1475 E:1476 ||| LS
)  ||| S:1476 E:1478 ||| -RRB-
fold  ||| S:1478 E:1483 ||| JJ
increase  ||| S:1483 E:1492 ||| NN
in  ||| S:1492 E:1495 ||| IN
overall  ||| S:1495 E:1503 ||| JJ
mortality  ||| S:1503 E:1513 ||| NN
compared  ||| S:1513 E:1522 ||| VBN
to  ||| S:1522 E:1525 ||| TO
patients  ||| S:1525 E:1534 ||| NNS
with  ||| S:1534 E:1539 ||| IN
baseline  ||| S:1539 E:1548 ||| JJ
SCPP  ||| S:1548 E:1553 ||| NN
levels  ||| S:1553 E:1560 ||| NNS
(  ||| S:1560 E:1561 ||| -LRB-
< ||| S:1561 E:1562 ||| SYM
1.92mmol ||| S:1562 E:1570 ||| NNP
( ||| S:1570 E:1571 ||| -LRB-
2 ||| S:1571 E:1572 ||| LS
) ||| S:1572 E:1573 ||| -RRB-
/ ||| S:1573 E:1574 ||| FW
l ||| S:1574 E:1575 ||| FW
( ||| S:1575 E:1576 ||| -LRB-
2 ||| S:1576 E:1577 ||| LS
) ||| S:1577 E:1578 ||| -RRB-
)  ||| S:1578 E:1580 ||| -RRB-
as  ||| S:1580 E:1583 ||| IN
reference  ||| S:1583 E:1593 ||| NN
category ||| S:1593 E:1601 ||| NN
.  ||| S:1601 E:1603 ||| .
Those  ||| S:1603 E:1609 ||| DT
findings  ||| S:1609 E:1618 ||| NNS
in  ||| S:1618 E:1621 ||| IN
our  ||| S:1621 E:1625 ||| PRP$
study  ||| S:1625 E:1631 ||| NN
population  ||| S:1631 E:1642 ||| NN
with  ||| S:1642 E:1647 ||| IN
3577  ||| S:1647 E:1652 ||| CD
patients  ||| S:1652 E:1661 ||| NNS
over  ||| S:1661 E:1666 ||| IN
a  ||| S:1666 E:1668 ||| DT
period  ||| S:1668 E:1675 ||| NN
of  ||| S:1675 E:1678 ||| IN
20  ||| S:1678 E:1681 ||| CD
years  ||| S:1681 E:1687 ||| NNS
proved  ||| S:1687 E:1694 ||| VBD
to  ||| S:1694 E:1697 ||| TO
be ||| S:1697 E:1699 ||| VB
,  ||| S:1699 E:1701 ||| ,
that  ||| S:1701 E:1706 ||| WDT
serum  ||| S:1706 E:1712 ||| VBZ
Ca  ||| S:1712 E:1715 ||| JJ
levels  ||| S:1715 E:1722 ||| NNS
may  ||| S:1722 E:1726 ||| MD
be  ||| S:1726 E:1729 ||| VB
a  ||| S:1729 E:1731 ||| DT
good  ||| S:1731 E:1736 ||| JJ
predictor  ||| S:1736 E:1746 ||| NN
for  ||| S:1746 E:1750 ||| IN
mortality  ||| S:1750 E:1760 ||| NN
in  ||| S:1760 E:1763 ||| IN
patients  ||| S:1763 E:1772 ||| NNS
with  ||| S:1772 E:1777 ||| IN
fracture  ||| S:1777 E:1786 ||| NN
of  ||| S:1786 E:1789 ||| IN
the  ||| S:1789 E:1793 ||| DT
proximal  ||| S:1793 E:1802 ||| JJ
femur ||| S:1802 E:1807 ||| NN
.  ||| S:1807 E:1809 ||| .
Further  ||| S:1809 E:1817 ||| JJ
studies  ||| S:1817 E:1825 ||| NNS
are  ||| S:1825 E:1829 ||| VBP
required  ||| S:1829 E:1838 ||| VBN
to  ||| S:1838 E:1841 ||| TO
evaluate  ||| S:1841 E:1850 ||| VB
whether  ||| S:1850 E:1858 ||| IN
these  ||| S:1858 E:1864 ||| DT
high  ||| S:1864 E:1869 ||| JJ
risk  ||| S:1869 E:1874 ||| NN
patients  ||| S:1874 E:1883 ||| NNS
might  ||| S:1883 E:1889 ||| MD
benefit  ||| S:1889 E:1897 ||| VB
from  ||| S:1897 E:1902 ||| IN
specific  ||| S:1902 E:1911 ||| JJ
therapeutic  ||| S:1911 E:1923 ||| JJ
measurements ||| S:1923 E:1935 ||| NNS
.  ||| S:1935 E:1937 ||| .
This  ||| S:1937 E:1942 ||| DT
prognostic  ||| S:1942 E:1953 ||| JJ
factor  ||| S:1953 E:1960 ||| NN
may  ||| S:1960 E:1964 ||| MD
help  ||| S:1964 E:1969 ||| VB
to  ||| S:1969 E:1972 ||| TO
increase  ||| S:1972 E:1981 ||| VB
the  ||| S:1981 E:1985 ||| DT
outcome  ||| S:1985 E:1993 ||| NN
of  ||| S:1993 E:1996 ||| IN
elderly  ||| S:1996 E:2004 ||| JJ
patients  ||| S:2004 E:2013 ||| NNS
with  ||| S:2013 E:2018 ||| IN
a  ||| S:2018 E:2020 ||| DT
fracture  ||| S:2020 E:2029 ||| NN
of  ||| S:2029 E:2032 ||| IN
the  ||| S:2032 E:2036 ||| DT
proximal  ||| S:2036 E:2045 ||| JJ
femur ||| S:2045 E:2050 ||| NN
.  ||| S:2050 E:2052 ||| .
